1Bravo EL, Kalmadi SR, Gill I. Clinical utility of temozolomide in the treatment of malignant paraganglioma: a preliminary report [J]. Horm Metab Res ,2009 ,41 (9) :703-736.
5Waguespack SG, Rich T, Grubbs E, et al. A current re-view of the etiology, diagnosis, and treatment of pediatric pheochromocytoma and paraganglioma [ J ]. J Clin En-docrinol Metab, 2010,95 ( 5 ) : 2023 -2037.
2Boyle M, Gaffney E F, Thurston A. Paraganglioma of the prostatic urethra. A report of three cases and a review of the literature [J]. Br J Urol, 1996, 77(3) :445-448.
3Pacak K, Eisenhofer G, Carrasquillo J A, et al. 6-[18F] fluorodopamine positron emission tomographic (PET) scanning for diagnostic localization of pheochromocytoma [ J]. Hypertension, 2001, 38(1): 6-8.
4Nieto Palacios A, Martinez Alvarez R, del Barco Mofillo E. Other therapeutic alternatives: radiotherapy and chemotherapy [J]. Aeta Otorrinolaringol Esp, 2009, 60 (Suppl 1): 130-136.
5Edstrom Elder E, Hjelm Skog A L, Hoog A, et al. The management of benign and malignant pheochromocytoma and abdominal paraganglioma [J]. Eur J Surg Oncol, 2003, 29(3) : 278-283.
6John H, Ziegler W H, Hauri D, et al. Pheochromoeytoma: can malignant potential be predicted [J]? Urology, 1999, 53(4):679- 683.
7Lucon A M, Falei R Jr, Praxedes J N, et al. Multcentric pheochromocytoma and involvement of the inferior vena cava [J].Sao Paulo Med J, 2001, 119(2) : 86-88.
8Lin S R, Lee Y I, Tasi J H. Mutations of the p53 gene in human Functional adrenal neoplasms [J]. J Clin Endocrinol Metab, 1999, 78(2): 483-491.
9Kubota Y, Nakada T, Sasagawa I, et al. Elevated levels of telomerase activity in malignant pheoehromoeytoma [J]. Caneer, 1998, 82(1) : 176-179.
10Joynt K E, Moslehi J J, Baughman K L. Paragangliomas: etiology, presentation, and management [J]. Cardiol Rev, 2009, 17 (4) :159-164.
